Impact of Elexacaftor-Tezacaftor-Ivacaftor on Bacterial Colonization and Inflammatory Responses in Cystic Fibrosis.
Shahid I SheikhRodney D BrittNancy A Ryan-WengerAiman Q KhanBrandon W LewisCourtney GushueHazel OzunaDevi JaganathanKaren S McCoyBenjamin T KoppPublished in: Pediatric pulmonology (2022)
In pwCF, ETI significantly improved clinical outcomes, reduced systemic pro-inflammatory cytokines, and restored circulating immune cell composition after 6 months of therapy. This article is protected by copyright. All rights reserved.